New enzyme therapy may shorten hospital stays for bone cancer patients
NCT ID NCT03960177
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This early-phase study tests whether glucarpidase can lower the toxic side effects of high-dose methotrexate in adults with osteosarcoma, a type of bone cancer. The goal is to help patients complete their planned chemotherapy doses and spend less time in the hospital. About 12 participants will receive glucarpidase alongside their standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill stall advanced sarcomas?
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?
- Experimental vaccine fights sarcoma with Patient's own immune cells
- New drug hope for rare sarcomas after chemo fails
- Dietary change explored as cancer support strategy